CLC Number:
| [1] Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan[J]. J Thromb Haemost, 2011: 283-301. doi:10.1111/j.1538-7836.2011.04341.x. [2] Roose E, Joly BS. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura[J]. Hamostaseologie, 2020, 40(3): 322-336. [3] Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic Purpura and other thrombotic microangiopathies[J]. Br J Haematol, 2012,158(3):323-335. [4] Roose E, Veyradier A, Vanhoorelbeke K. Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic Purpura diagnosis and management[J]. Curr Opin Hematol, 2020, 27(5): 320-326. [5] Matsumoto M, Fujimura Y, Wada H, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic Purpura(TTP)2017 in Japan[J]. Int J Hematol, 2017, 106(1): 3-15. [6] Jiang Y, Huang D. Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13[J]. J Cell Mol Med, 2020, 24(7): 4356-4361. [7] Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic Purpura patients treated in the United Kingdom[J]. J Thromb Haemost, 2012, 10(9):1792-1801. [8] Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic Purpura[J]. Nature, 2001,413(6855):488-494. [9] Singh B, Chan KH, Kaur P, et al. Atypical Presentation of Thrombotic Thrombocytopenic Purpura without Hematological Features[J]. Int J Hematol Oncol Stem Cell Res, 2020,14(3):167-170. [10] Azoulay E, Bauer PR, Mariotte E, et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic Purpura[J].Intensive Care Med, 2020, 46(3): 570-571. [11] Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic Purpura[J]. J Thromb Haemost, 2020,18(10):2496-2502. [12] Marcellini AS, Valencia CS, Díaz VJ, et al. Clinical management and follow-up of relapsed immune thrombotic thrombocytopenic Purpura during pregnancy:A case report[J]. T hromb Res, 2020,194:91-94. doi:10.1016/j.thromres.2020.06.020. [13] Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic Purpura[J]. J Thromb Haemost, 2020,18(10):2486-2495. [14] Wynick C, Britto J, Sawler D, et al. Validation of the PLASMIC score for predicting ADAMTS13 activity<10% in patients with suspected thrombotic thrombocytopenic Purpura in Alberta, Canada[J]. Thromb Res,2020,196:335-339. doi:10.1016/j.thromres.2020.09.012. |
| [1] | LIU Lu, LIU Chuan-fang, WANG Min, TIAN Tian, YU Shuang, HE Na, SUN Yuan-xin, MA Dao-xin. The aberrant expression of microRNA-181a, microRNA-146a, microRNA-326 and microRNA-142-3p in peripheral blood of patients with immune thrombocytopenia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 55-60. |
| [2] | ZHANG Chun-qing, WANG Lin, QIN Ping, CHEN Feng, CHEN Chun-yan, HOU Ming. Clinical efficacy and safety of rhTPO in the treatment of idiopathic thrombocytopenic purpura: a randomized controlled trial [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(7): 117-. |
| [3] | XU Cui-ping1，LI Zhen2，SONG Jie3，ZHANG Dan2，ZHU Qing-jun2. Effect of traditional Chinese medicine for kidney-reinforcingof morphological alterations of the adrenal gland in mice with Kidney-Yang deficiency [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(2): 67-70. |
|
||
